Heat helps cancer drugs battle cancer

May 10, 2011 by Deborah Braconnier report

(PhysOrg.com) -- Localized hyperthermia has been used occasionally with cancer drugs for some time, but until now, the reason it helps has been a mystery. In a report in the Proceedings of the National Academy of Sciences, scientists have discovered that the addition of heat inhibits homologous recombination so the cancer cells are unable to repair DNA damage caused by the cancer treatments.

Originally used in the 70s and 80s, hyperthermia showed promise in inhibiting the repair mechanism, though clinical trials at the time were unable to establish a definitive connection and interest in the combination diminished. However, new technology and clinical trials have brought it back into the spotlight, and this new study may just give it the fuel it needs.

Przemek Krawczyk from the University of Amsterdam and his team studied tumor cells both in a and those injected into rats. They discovered that when the cells were heated to 106-109 degrees Fahrenheit, the protein BRCA2 (essential for repair pathway) was degraded and thus blocked homologous recombination.

This new finding opens up the possibility for a new type of drug, called PARP, to have a wider range of possible cancer treating options. PARP is currently under clinical trials to treat a certain type of hereditary breast cancer. In this particular cancer, BRCA1 is mutated and already unable to repair . PARP is specifically designed to attack these already mutated tumor cells.

If hyperthermia is able to cause the same type of defect in , the door could be opened for PARP to be used to treat many other cancers. PARP has shown to be well tolerated by many patients with very few side effects compared to current chemotherapy treatments.

Explore further: New class of cancer drugs could work in colon cancers with genetic mutation, study finds

More information: Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition, PNAS, Published online before print May 9, 2011, doi: 10.1073/pnas.1101053108

Abstract
Defective homologous recombination (HR) DNA repair imposed by BRCA1 or BRCA2 deficiency sensitizes cells to poly (ADP-ribose) polymerase (PARP)-1 inhibition and is currently exploited in clinical treatment of HR-deficient tumors. Here we show that mild hyperthermia (41–42.5 °C) induces degradation of BRCA2 and inhibits HR. We demonstrate that hyperthermia can be used to sensitize innately HR-proficient tumor cells to PARP-1 inhibitors and that this effect can be enhanced by heat shock protein inhibition. Our results, obtained from cell lines and in vivo tumor models, enable the design of unique therapeutic strategies involving localized on-demand induction of HR deficiency, an approach that we term induced synthetic lethality.

Related Stories

New class of cancer drugs could work in colon cancers with genetic mutation, study finds

April 25, 2011
A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.